Medpace (MEDP) closed the latest trading day at $339.38, indicating a +1.08% change from the previous session's end. This change lagged the S&P 500's 1.16% gain on the day. Elsewhere, the Dow gained 1.2%, while the tech-heavy Nasdaq added 1.16%. Shares of the provider of outsourced clinical development services have depreciated by 13.17% over the course of the past month, underperforming the Medical sector's gain of 4.5% and the S&P 500's gain of 3.48%. Analysts and investors alike will be keeping a close e ...

I I F ■ F Matteo Colombo Investment update Following my January '23 publication rating Medpace Holdings (NASDAQ:MEDP) a buy, the stock is +69% and has vindicated the original buy thesis presented in July '22 (I had reinstated the buy rating several times in between these two dates as well). The January publication outlined numerous investment facts that are still explicitly relevant in the investment debate today, namely: Profitability is a standout with ROICs at +33% trailing return on invested capital dri ...

NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP) on behalf of Medpace stockholders. Our investigation concerns whether Medpace has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On July 22, 2024, after market hours, Medpace released its secon ...

SAN FRANCISCO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Medpace Holdings, Inc. (NASDAQ: MEDP) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Visit: www.hbsslaw.com/investor-fraud/MEDP Contact the Firm Now: MEDP@hbsslaw.com 844-916-0895 Medpace Holdings, Inc. (MEDP) Investigation: Medpace Holdings, Inc. is facing scrutiny over its recent financial perform ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task. Medpace (MEDP) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. While the historical EPS growth rate for Medpace is 32.2%, investors should actually focus o ...

Company Participants Conference Call Participants Operator I would now like to introduce your host for today's conference call, Lauren Morris, Medpace's Director of Investor Relations. You may begin. Good morning, and thank you for joining Medpace's second quarter 2024 earnings conference call. Also on the call today is our CEO, August Troendle; our President, Jesse Geiger; and our CFO, Kevin Brady. During this call, we will also be referring to certain non-GAAP financial measures. These non-GAAP measures a ...

| --- | --- | |-------|-------| | | | | | | | | | This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our forecasted financial results and the effective tax rate used for non-GAAP adjustment purposes. In this context, forward-looking state ...

2024 Financial Guidance To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call. Forward-Looking Statements These and other important factors discussed under ...

During the first quarter of 2024, Medpace witnessed a robust revenue uptick year over year on the back of a strong backlog conversion rate. Its net new business awards were also strong during the period. We expect the company to have continued to register strong backlog addition in the second quarter. On its first-quarter earnings call in April, the company projected backlog conversion of approximately $1.56 billion to revenues in 12 months. This is likely to have reflected in the second-quarter result. Cen ...

The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on April 22, 2024, Medpace reported EPS of $3.2 versus consensus estimate of $2.45 while it missed the consensus revenue estimate by 0.33%. Medpace may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is ...